RESUMO
BACKGROUND: The effectiveness of cycloplegia in delaying the progression of myopia and its application in refractive examination in children have been extensively studied, but there are still few studies on the effects of atropine/tropicamide on ocular biological parameters. Therefore, the purpose of this study was to explore the effects of atropine/tropicamide on children's ocular biological parameters in different age groups and the differences between them. METHODS: This was a prospective observational study in which all school children were examined for dioptres and ocular biological parameters in the outpatient clinic, and 1% atropine or tropicamide was used for treatment. After examination, we enrolled the patients grouped by age (age from 2 to 12 years treated by atropine, 55 cases; age from 2 to 10 years treated by tropicamide, 70 cases; age from 14 to 17 years treated by tropicamide, 70 cases). The ocular biological parameters of each patient before and after cycloplegia were measured, and the difference and its absolute value were calculated for statistical analysis using an independent-samples t test. RESULTS: We compared the value and the absolute value of the differences in ocular biological parameters before and after cycloplegia in the same age group, and we found that the differences were not statistically significant (P > 0.05). There were significant differences in the corresponding values of AL, K1 and ACD among the different age groups (P < 0.05). Before cycloplegia, there were significant differences in AL, K, K1, K2 and ACD in different age groups (P < 0.05). However, the differences in AL, K, K1, K2 and ACD among different age groups disappeared after cycloplegia (P > 0.05). CONCLUSIONS: This study demonstrated that atropine/tropicamide have different effects on cycloplegia in children of different ages. The effects of atropine/tropicamide on ocular biological parameters should be fully considered when evaluating the refractive state before refractive surgery or mydriasis optometry for children of different ages.
Assuntos
Presbiopia , Tropicamida , Humanos , Criança , Pré-Escolar , Adolescente , Tropicamida/farmacologia , Atropina/farmacologia , Midriáticos/farmacologia , Refração Ocular , Corpo CiliarRESUMO
BACKGROUND: To demonstrate the safety and efficacy of the intracameral use of tropicamide 0.02%/phenylephrine 0.31%/lidocaine 1% in pediatric cataract surgery, a combination widely used in adult patients but still off-label in children. METHODS: Design: two-center, prospective, observational study. SETTING: San Giuseppe Hospital, Milan and Meyer Children's Hospital, Florence. STUDY POPULATION: children from 0 to 4 years of age undergoing cataract surgery with or without intraocular IOL implantation, in the absence of clinically significant systemic conditions, history of ocular surgery, concurrent ocular medication, hypersensitivity to any of the substances and post-traumatic cataracts. During the surgery, patients received the combination drug after the primary access to the anterior chamber. Efficacy was evaluated by achieving an adequate mydriasis in order to perform capsulorhexis, while safety was assessed by recording vital signs (heart rate, blood pressure, respiratory rate, temperature) pre- and post-administration of the substance. RESULTS: This study included 53 surgical procedures of 36 patients: 41 eyes were left aphakic, while 12 eyes received primary IOL implantation. The pupil size was adequate to safely perform capsulorhexis in 52 procedures of 53. The difference in pupil enlargement was significant (6.0 ± 1.14 mm, P = < 0.001). There were no notable changes in vital parameters. CONCLUSIONS: The administration of intracameral tropicamide 0.02%/phenylephrine 0.31%/lidocaine 1% in pediatric cataract surgery is effective for obtaining an adequate mydriasis without any vital parameters changes throughout the procedure.
Assuntos
Catarata , Midríase , Oftalmologia , Facoemulsificação , Adulto , Humanos , Criança , Tropicamida/farmacologia , Midriáticos , Estudos Prospectivos , Fenilefrina , Pupila/fisiologia , Lidocaína/efeitos adversos , Facoemulsificação/métodosRESUMO
BACKGROUND: Cyclopentolate is frequently used as a mydriatic agent during ophthalmological examinations in childhood and hypersensitivity reactions associated with this drug are rare. We aim to report an infant who experienced anaphylaxis due to cyclopentolate eye drops. CASE: A nine-month-old girl, who was being followed up with a diagnosis of retinoblastoma, presented for consultation for urticaria, cough, stridor, and dyspnea that developed after the administration of topical cyclopentolate to the eyes. The patient was diagnosed with anaphylaxis and treated with adrenaline. During the follow-up, tropicamide was used safely as an alternative drug. CONCLUSIONS: In children, hypersensitivity reactions due to cyclopentolate are very rare. Only four pediatric patients were reported in the literature to have developed an allergic reaction after the administration of cyclopentolate eye drops. We present here the youngest patient who developed anaphylaxis with cyclopentolate eye drops. Anaphylaxis due to cyclopentolate should be kept in mind, rapidly recognized, and treated when a reaction develops.
Assuntos
Anafilaxia , Ciclopentolato , Lactente , Feminino , Humanos , Criança , Ciclopentolato/efeitos adversos , Soluções Oftálmicas/efeitos adversos , Anafilaxia/induzido quimicamente , Anafilaxia/diagnóstico , Tropicamida/farmacologia , Midriáticos/efeitos adversosRESUMO
Corneal stability is essential for contact lenses and refractive surgery. It seems that paralyzing eye drops or expansion of the ciliary muscle affect the radius of curvature and the strength of the cornea, and this effect is to increase the strength of the cornea during muscle spasm and decrease it in the relaxed state of the muscle. On the other hand, different factors (such as contact lens wear, ocular surface disorders, trauma, dry eye, and immunosuppression) could alter the immune defense mechanisms of the outer eye and permit microorganisms to invade the cornea. Therefore, the present study compared Pilocarpine and tropicamide drop on corneal topography and their effect on IL-6 and TNF-α levels in tear. This prospective study was performed on sixty normal and healthy eyes of sixty volunteers with a mean age of 38.19 years and without any ocular pathology. Volunteers were divided into two groups of thirty. In the first group, corneal topography of both eyes was measured before and 30 minutes after instillation of topical tropicamide 1% in only one eye. The other eye was the control eye, and no drop was given. The same routine was performed in the second group, except that subject received one drop of Pilocarpine 2% in one eye. Statistical comparison between groups for the central corneal power, corneal radius, and corneal astigmatism was performed using paired t-test. IL-6 and TNF-α levels in tear were analyzed using two Luminex commercial assays with Bio-Plex 200TM System (Bio-Rad, Hercules, California, USA). In group 1, no significant changes were found in corneal radius, power, and astigmatism. However, in group 2 subjects who received pilocarpine eye drops, the mean corneal radius value decreased significantly by 0.05 mm. The mean corneal power increased by +0.32 D. There was no significant difference change in corneal astigmatism in both groups. Evaluation of IL-6 levels in tears showed a significant difference between the control and treatment groups (P = 0.041). But no significant difference was observed between the Pilocarpine and the Tropicamide groups (P = 0.761). Evaluation of TNF-α level in tears also showed no significant difference between these groups (P = 0.088). Pilocarpine induced ciliary muscle contraction, which may cause pressure on the corneal limbus and scleral spur, resulting in changes in corneal curvature. But tropicamide eye drop did not affect corneal radius and other corneal parameters, and corneal topography can be carried out after the installation of tropicamide eye drop.
Assuntos
Astigmatismo , Tropicamida , Adulto , Astigmatismo/patologia , Córnea/patologia , Topografia da Córnea , Humanos , Interleucina-6/farmacologia , Soluções Oftálmicas/farmacologia , Pilocarpina/farmacologia , Estudos Prospectivos , Tropicamida/farmacologia , Fator de Necrose Tumoral alfa/farmacologiaRESUMO
The epithelial-mesenchymal transition (EMT) plays a significant role in fibrosis and migration of lens epithelial cells (LECs), and eventually induces posterior capsule opacification (PCO). In the past, it was generally believed that the TGF-ß/Smad pathway regulates lens EMT. A recent study found that attenuated glutathione level promotes LECs EMT via the Wnt/ß-catenin pathway, which suggests a more complex pathogenesis of PCO. To test the hypothesis, we used the mouse cataract surgery PCO model and tested both canonical Wnt/ß-catenin and TGF-ß/Smad signaling pathways. The results showed that both TGF-ß/Smad and Wnt/ß-catenin pathways were activated during the lens capsule fibrosis. Compared with the freshly isolated posterior capsule, the expression level of phosphorylated Smad2 was highest at day3 and then slightly decreased, but the expression level of Wnt10a gradually increased from day0 to day7. It shows that these two pathways are involved in the lens epithelium's fibrotic process and may play different roles in different periods. Subsequently, we established oxidative stress-induced EMT model in primary porcine lens epithelial cells and found that both the TGF-ß/Smad and Wnt/ß-catenin pathways were activated. Further study suggests that block Wnt/ß-catenin pathway using XAV939 alone or block TGF-ß/Smad pathway using LY2109761 could partially block pLECs fibrosis, but blocking Wnt/ß-catenin and TGF-ß/Smad pathway using combined XAV939 and LY2109761 could completely block pLECs fibrosis. In conclusion, this study demonstrates that both TGF-ß/Smad and canonical Wnt/ß-catenin pathways play a significant role in regulating epithelial-mesenchymal transformation of lens epithelial cells but might be in a different stage.
Assuntos
Opacificação da Cápsula/metabolismo , Células Epiteliais/metabolismo , Transição Epitelial-Mesenquimal , Cristalino/metabolismo , Estresse Oxidativo , Fator de Crescimento Transformador beta1/metabolismo , beta Catenina/metabolismo , Animais , Antioxidantes/metabolismo , Catarata , Proliferação de Células , Sobrevivência Celular , Modelos Animais de Doenças , Fibrose , Humanos , Camundongos , Oxigênio/metabolismo , Pirazóis/farmacologia , Pirróis/farmacologia , Suínos , Fator de Crescimento Transformador beta/metabolismo , Tropicamida/farmacologia , Via de Sinalização Wnt/efeitos dos fármacosRESUMO
The acetylcholine muscarinic 4 (M4) receptor is a principal muscarinic receptor subtype present in the striatum. Notably, Gαi/o-coupled M4 receptors and Gαs/Golf-coupled dopamine D1 receptors are coexpressed in striatonigral projection neurons and are thought to interact with each other to regulate neuronal excitability, although underlying molecular mechanisms are poorly understood. In this study, we investigated the role of M4 receptors in the regulation of phosphorylation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in the rat normal and dopamine-stimulated striatum in vivo. We found that a systemic injection of a M4 antagonist tropicamide increased AMPA receptor GluA1 subunit phosphorylation at a protein kinase A-dependent site (S845) in the striatum. The tropicamide-induced S845 phosphorylation was rapid, reversible, and dose-dependent and occurred in the two subdivisions of the striatum, i.e., the caudate putamen and nucleus accumbens. Coadministration of subthreshold doses of tropicamide and a D1 agonist SKF81297 induced a significant increase in S845 phosphorylation. Coadministered tropicamide and a dopamine psychostimulant amphetamine at their subthreshold doses also elevated S845 phosphorylation. Tropicamide alone or coinjected with SKF81297 or amphetamine had no effect on GluA1 phosphorylation at S831. Tropicamide did not affect GluA2 phosphorylation at S880. These results reveal a selective inhibitory linkage from M4 receptors to GluA1 in S845 phosphorylation in striatal neurons. Blockade of the M4-mediated inhibition significantly augments constitutive and dopamine-stimulated GluA1 S845 phosphorylation.
Assuntos
Corpo Estriado/metabolismo , Receptor Muscarínico M4/metabolismo , Receptores de AMPA/metabolismo , Anfetamina/farmacologia , Animais , Benzazepinas/farmacologia , Corpo Estriado/efeitos dos fármacos , Proteínas Quinases Dependentes de AMP Cíclico/metabolismo , Relação Dose-Resposta a Droga , Masculino , Neurotransmissores/farmacologia , Fosforilação/efeitos dos fármacos , Fosforilação/fisiologia , Ratos Wistar , Receptores de Dopamina D1/antagonistas & inibidores , Receptores de Dopamina D1/metabolismo , Tropicamida/farmacologiaRESUMO
PURPOSE: To determine the effect of cyclopentolate, tropicamide, and artificial tear drops on higher-order aberrations (HOAs) in normal eyes with OPD-Scan III (Nidek Inc., Tokyo, Japan). METHODS: In this study, 189 eyes of individuals aged 20 to 35 years were selected as samples. Inclusion criteria were a corrected visual acuity of 20/20 or better, a minimum size of about 5 mm for the pupil in the dark, hyperopia and myopia less than 5 D, and astigmatism less than 2 D. Moreover, participants with pathological eye problems, a history of intraocular surgery, and ocular diseases affecting the accommodation, pupil size, and corneal surface were excluded. Higher-order aberrations of the participants were assessed by the OPD-Scan III before and after cyclopentolate (Colircuss), tropicamide (Mydrax 0.5%), and artificial tears (Tearlose) drop instillation. RESULTS: After instilling cyclopentolate drops, the mean of the total root mean square (RMS) increased from 4.580 to 6.335 D, total spherical aberration increased from 0.155 to 0.381 D, and total coma increased from 0.195 to 0.369 D; the increases were significant for total RMS and total spherical aberration, but a significant relationship was not seen with total coma. After tropicamide, the mean aberrations of total RMS increased from 4.301 to 4.568 D, total spherical aberration increased from 0.146 to 0.160 D, and total coma increased from 0.213 to 0.230 D; the increase was only significant for total coma. On the other hand, after artificial tears, the average of all aberrations decreased in a nonsignificant manner. CONCLUSION: Most changes of mean aberrations were related to cyclopentolate drops. Tropicamide and artificial tears had the second and third rank according to their effect on mean errors. As a result, it seems that ocular accommodation is the most important impact on HOA than pupil size. However, the pupil size is the second factor for HOAs.
Assuntos
Córnea/efeitos dos fármacos , Aberrações de Frente de Onda da Córnea/induzido quimicamente , Ciclopentolato/farmacologia , Lubrificantes Oftálmicos/farmacologia , Antagonistas Muscarínicos/farmacologia , Midriáticos/farmacologia , Tropicamida/farmacologia , Adulto , Análise de Variância , Feminino , Humanos , Masculino , Pupila/efeitos dos fármacos , Adulto JovemRESUMO
PURPOSE: The study was performed to study the effect of cycloplegia on anterior chamber depth (ACD) in cataract eyes. One instrument (Lenstar) was used for all measurements. METHODS: Anterior chamber depth calculations were taken with the Lenstar in cataract eyes with a mean age of 71.9±8.8 years before instilling cycloplegic drops. Two drops of Tropicamide were then instilled in each eye and measurements were retaken between 30 to 45 min later. RESULTS: Cycloplegia with a mild agent used routinely in this practice location showed a statically significant effect on increasing ACD by 0.0647±0.01 in the OD and 0.0758±0.02 in the OS. CONCLUSIONS: Anterior chamber depth can be important in the final refractive result postcataract surgery. The results of a change in effective lens position would be most significant in higher intraocular lens powers.
Assuntos
Câmara Anterior/efeitos dos fármacos , Midriáticos/farmacologia , Tropicamida/farmacologia , Idoso , Idoso de 80 Anos ou mais , Câmara Anterior/anatomia & histologia , Extração de Catarata/métodos , Feminino , Humanos , Implante de Lente Intraocular/métodos , Masculino , Pessoa de Meia-IdadeRESUMO
PURPOSE: To determine whether pupil dilation affects biometric measurements and intraocular lens (IOL) power calculation made using the new swept-source optical coherence tomography-based optical biometer (IOLMaster 700©; Carl Zeiss Meditec, Jena, Germany). PROCEDURES: Eighty-one eyes of 81 patients evaluated for cataract surgery were prospectively examined using the IOLMaster 700© before and after pupil dilation with tropicamide 1%. The measurements made were: axial length (AL), central corneal thickness (CCT), aqueous chamber depth (ACD), lens thickness (LT), mean keratometry (MK), white-to-white distance (WTW) and pupil diameter (PD). Holladay II and SRK/T formulas were used to calculate IOL power. Agreement between measurement modes (with and without dilation) was assessed through intraclass correlation coefficients (ICC) and Bland-Altman plots. RESULTS: Mean patient age was 75.17±7.54 years (range: 57-92). Of the variables determined, CCT, ACD, LT and WTW varied significantly according to pupil dilation. Excellent intraobserver correlation was observed between measurements made before and after pupil dilation. Mean IOL power calculation using the Holladay 2 and SRK/T formulas were unmodified by pupil dilation. CONCLUSIONS: The use of pupil dilation produces statistical yet not clinically significant differences in some IOLMaster 700© measurements. However, it does not affect mean IOL power calculation.
Assuntos
Comprimento Axial do Olho/efeitos dos fármacos , Comprimento Axial do Olho/diagnóstico por imagem , Biometria , Lentes Intraoculares , Tomografia de Coerência Óptica , Tropicamida/farmacologia , Idoso , Idoso de 80 Anos ou mais , Comprimento Axial do Olho/anatomia & histologia , Biometria/instrumentação , Biometria/métodos , Catarata/patologia , Dilatação/efeitos adversos , Dilatação/métodos , Feminino , Humanos , Cristalino/anatomia & histologia , Cristalino/diagnóstico por imagem , Cristalino/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Pupila/efeitos dos fármacos , Tomografia de Coerência Óptica/instrumentação , Tomografia de Coerência Óptica/métodosRESUMO
OBJECTIVES: The aim of this study was to evaluate the effect of topical tropicamide at two concentrations (0.5% and 1.0%) on the Schirmer tear test (STT) results in clinically normal cats. METHODS: Twenty-four adult domestic shorthair cats were randomly assigned to three groups. In all three groups, ophthalmic solutions were instilled in a randomly selected eye and the opposite eye served as the control. In groups 1, 2 and 3 one drop of 0.5% tropicamide, 1.0% tropicamide and distilled water was used, respectively. Tear production in both eyes was tested 30 and 60 mins after instillation in all three groups. RESULTS: Baseline mean ± SEM STT values for the treated eyes in groups 1, 2 and 3 were 13.37 ± 2.91 mm/min, 10.87 ± 1.39 mm/min and 11.37 ± 1.65 mm/min, respectively. Thirty minutes after the drug instillation in the treated eye, mean ± SEM STT values in groups 1, 2 and 3 were 4.87 ± 3.05 mm/min, 2.00 ± 0.84 mm/min and 11.25 ± 1.81 mm/min, respectively. The mean ± SEM STT levels of the treated eye after 60 mins were 3.75 ± 1.87 mm/min, 0.5 ± 0.37 mm/min and 11.42 ± 1.78 mm/min in groups 1, 2 and 3, respectively. CONCLUSIONS AND RELEVANCE: Use of 0.5% topical tropicamide, instead of 1.0% tropicamide, as a mydriatic agent, can be recommended in cats. Tear production measurement should be performed prior to the administration of tropicamide, regardless of the concentration of this drug.
Assuntos
Gatos/fisiologia , Midriáticos/farmacologia , Soluções Oftálmicas/farmacologia , Lágrimas/efeitos dos fármacos , Tropicamida/farmacologia , Administração Tópica , Animais , Relação Dose-Resposta a Droga , Feminino , Masculino , Midriáticos/administração & dosagem , Soluções Oftálmicas/administração & dosagem , Tropicamida/administração & dosagemRESUMO
GPR37, also known as parkin associated endothelin-like receptor (Pael-R), is an orphan GPCR that aggregates intracellularly in a juvenile form of Parkinson's disease. However, little is known about the function of this orphan receptor. Here, using a model for parkisonian tremor, the pilocarpine-induced tremulous jaw movements (TJMs), we show that the deletion of GPR37 attenuated the TJMs in response to this cholinomimetic. Interestingly, the control that adenosine A2A receptor exerted over TJMs was lost in the absence of GPR37, thus pointing to a pivotal role of this orphan receptor in the adenosinergic control of parkinsonian tremor.
Assuntos
Arcada Osseodentária/fisiopatologia , Transtornos Parkinsonianos/fisiopatologia , Receptor A2A de Adenosina/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Tremor/fisiopatologia , Antagonistas do Receptor A2 de Adenosina/farmacologia , Animais , Arcada Osseodentária/efeitos dos fármacos , Masculino , Camundongos Endogâmicos C57BL , Camundongos Knockout , Movimento/efeitos dos fármacos , Movimento/fisiologia , Antagonistas Muscarínicos/farmacologia , Transtornos Parkinsonianos/tratamento farmacológico , Pilocarpina , Pirimidinas/farmacologia , Receptores Acoplados a Proteínas G/genética , Tremor/tratamento farmacológico , Triazóis/farmacologia , Tropicamida/farmacologiaRESUMO
The present study aims to investigate the therapeutic effects of LXM-10 by intragastric administration in both acute and chronic inflammatory models, and to explore the underlying molecular mechanisms. The results showed that LXM-10 produced significant anti-inflammatory effects on carrageenan induced paw edema and complete Freund's adjuvant (CFA) induced arthritis, in which LXM-10 inhibited paw swelling in a dose- and time-dependent manner. ELISA analysis showed the production of pro-inflammatory cytokines including TNF-α and IL-6 was decreased by LXM-10. Western blot analysis showed that LXM-10 significantly reduced phosphorylation of Janus kinase 2 (JAK2) and further blunted phosphorylation of signal transducer and activator of transcription-3 (STAT3). The effects that LXM-10 had shown were attenuated by methyllycaconitine citrate (an α7 nicotinic acetylcholine receptor antagonist) or tropicamide (an M4 muscarinic acetylcholine receptor antagonist) in vivo. In conclusion, the studies showed that intragastric administration of LXM-10 exerted significant anti-inflammation effects in acute and chronic models, which may be attribute to the activation of α7 nicotinic acetylcholine receptor and M4 muscarinic acetylcholine receptor, thereby inhibiting the JAK2/STAT3 signal pathway, and ultimately reducing the production of pro-inflammatory cytokines of TNF-α and IL-6.
Assuntos
Anti-Inflamatórios/uso terapêutico , Janus Quinase 2/metabolismo , Piperazinas/uso terapêutico , Receptor Muscarínico M4/metabolismo , Fator de Transcrição STAT3/metabolismo , Compostos de Espiro/uso terapêutico , Receptor Nicotínico de Acetilcolina alfa7/metabolismo , Aconitina/análogos & derivados , Aconitina/farmacologia , Animais , Anti-Inflamatórios/farmacologia , Carragenina , Edema/induzido quimicamente , Edema/tratamento farmacológico , Mediadores da Inflamação/fisiologia , Interleucina-6/fisiologia , Masculino , Antagonistas Muscarínicos/farmacologia , Antagonistas Nicotínicos/farmacologia , Fosforilação , Piperazinas/farmacologia , Processamento de Proteína Pós-Traducional , Ratos , Ratos Sprague-Dawley , Transdução de Sinais , Compostos de Espiro/farmacologia , Tropicamida/farmacologia , Fator de Necrose Tumoral alfa/fisiologiaRESUMO
PURPOSE: To evaluate the effect of α1-adrenergic receptor antagonists (α1-ARAs) on pupil diameter and determine whether the diameter predicts intraoperative floppy-iris syndrome (IFIS). SETTING: Ophthalmology Section, Palermo University, Palermo, Italy. DESIGN: Prospective cohort study. METHODS: Male outpatients taking tamsulosin, α(1)-ARAs, or no α(1)-ARAs having phacoemulsification were recruited. Pupils were measured 1 month preoperatively, immediately preoperatively, and postoperatively under mesopic low (0.4 lux) and high (4.0 lux) illumination after pharmacologic dilation. The IFIS severity was graded. RESULTS: Each group comprised 50 patients. Pharmacologic dilation in both α(1)-ARA groups was statistically significantly less than in the no α1-ARA group 1 month preoperatively, immediately before surgery, and postoperatively (P=.001, P<.0005, and P<.0005, respectively). The IFIS incidence differed significantly between the tamsulosin and other α(1)-ARA groups and the no α1-ARA group (P<.0005 and P=.017, respectively) and between the tamsulosin group and the other α1-ARA group (P=.027). On regression analysis, the hazard ratio for overall IFIS incidence was 3.8 in the other α(1)-ARA group (P=.012) and 10.1 in the tamsulosin group (P<.0005). Pupil size was inversely related to IFIS incidence and severity (P<.0005). A dilated pupil of 7.0 mm or smaller had 73% sensitivity and 95% specificity for predicting IFIS (P=.0001). CONCLUSIONS: Pupil dilation was inhibited by α(1)-ARAs, in particular tamsulosin. For a pupil 7.0 mm or smaller, the risk for IFIS existed regardless of α(1)-ARAs treatment, which surgeons should take into consideration.
Assuntos
Antagonistas de Receptores Adrenérgicos alfa 1/efeitos adversos , Complicações Intraoperatórias , Doenças da Íris/diagnóstico , Midriáticos/farmacologia , Facoemulsificação , Pupila/efeitos dos fármacos , Idoso , Estudos de Coortes , Doxazossina/efeitos adversos , Combinação de Medicamentos , Humanos , Doenças da Íris/induzido quimicamente , Masculino , Músculo Liso/efeitos dos fármacos , Fenilefrina/farmacologia , Prazosina/efeitos adversos , Prazosina/análogos & derivados , Valor Preditivo dos Testes , Estudos Prospectivos , Fatores de Risco , Sensibilidade e Especificidade , Sulfonamidas/efeitos adversos , Síndrome , Tansulosina , Tropicamida/farmacologiaRESUMO
PURPOSE: The aim of this study was to evaluate the mydriatic effects of intracameral 1% lidocaine compared with 1:100,000 epinephrine and the effect on endothelial apoptosis in rabbits. METHODS: Forty eyes of 20 New Zealand white rabbits were divided into 2 equal groups. In the first group, 1 eye was injected intracamerally with 1% lidocaine (lidocaine eyes) and the fellow eye with 1:100,000 epinephrine (epinephrine eyes). In the second group, 1 eye was injected with balanced salt solution (BSS eye) and the fellow eye was instilled with 1% tropicamide (mydriatics eye). Specular microscopy, transmission electron microscopy, scanning electron microscopy, and TdT-mediated dUTP nick-end labeling staining were performed 1 day postinjection. RESULTS: Both the full-dilation time and pupil diameters of the lidocaine and epinephrine eyes were not significantly different (P > 0.05). The endothelial cytoplasmic vacuolizations were increased and microprojections were diminished in the epinephrine eyes compared with the mydriatics, BSS, and lidocaine eyes (P < 0.05). Apoptosis was demonstrated in only epinephrine eyes, with an index of 5%. CONCLUSIONS: In rabbits, the intracameral injections of preservative-free 1% lidocaine may be used as an adjunctive method with topical mydriatics in cataract surgery, as like 1:100,000 epinephrine. The intracameral 1% lidocaine may induce less microstructural alterations to the corneal endothelial cells than 1:100,000 epinephrine.
Assuntos
Epinefrina/farmacologia , Lidocaína/farmacologia , Midriáticos/farmacologia , Pupila/efeitos dos fármacos , Animais , Apoptose/efeitos dos fármacos , Extração de Catarata/métodos , Endotélio Corneano/efeitos dos fármacos , Endotélio Corneano/metabolismo , Epinefrina/administração & dosagem , Marcação In Situ das Extremidades Cortadas , Injeções , Lidocaína/administração & dosagem , Microscopia/métodos , Microscopia Eletrônica de Varredura , Microscopia Eletrônica de Transmissão , Midriáticos/administração & dosagem , Coelhos , Tropicamida/administração & dosagem , Tropicamida/farmacologiaRESUMO
We demonstrate that patients with primary Sjögren's syndrome (pSS) produce functional IgG autoantibodies that interact with the glandular M(3) muscarinic acetylcholine receptors (mAChRs). These autoantibodies act as a partial muscarinic agonist, increasing prostaglandin E(2) (PGE(2)) and cyclic AMP production through modifying Na(+)/K(+)-ATPase activity, but also interfere with the secretory effect of the parasympathetic neurotransmitter. The IgG from patients with pSS has two effects on the submandibular gland. On the one hand, it may act as an inducer of the proinflammatory molecule (PGE(2)) that, in turn, inhibits Na(+)/K(+)-ATPase activity. On the other hand, it plays a role in the pathogenesis of dry mouth, abolishing the Na(+)/K(+)-ATPase inhibition and the net K(+) efflux stimulation of the salivary gland in response to the authentic agonist pilocarpine, decreasing salivary fluid production.
Assuntos
Autoanticorpos/imunologia , AMP Cíclico/metabolismo , Dinoprostona/metabolismo , Imunoglobulina G/imunologia , Agonistas Muscarínicos/imunologia , Receptor Muscarínico M3/imunologia , Síndrome de Sjogren/imunologia , ATPase Trocadora de Sódio-Potássio/metabolismo , Glândula Submandibular/enzimologia , Adulto , Animais , Células Cultivadas , Feminino , Humanos , Fatores Imunológicos/imunologia , Mediadores da Inflamação/imunologia , Ceratoconjuntivite Seca/imunologia , Masculino , Pessoa de Meia-Idade , Agonistas Muscarínicos/farmacologia , Antagonistas Muscarínicos/farmacologia , Pilocarpina/farmacologia , Piperidinas/farmacologia , Pirenzepina/farmacologia , Potássio/metabolismo , Ratos , Ratos Wistar , ATPase Trocadora de Sódio-Potássio/antagonistas & inibidores , Glândula Submandibular/efeitos dos fármacos , Glândula Submandibular/metabolismo , Tropicamida/farmacologia , Xerostomia/imunologiaRESUMO
BACKGROUND: Ca(2+) in the central nervous system plays important roles in brain physiology, including neuronal survival and regeneration in rats with injured facial motoneurons. The present research was to study the modulations of intracellular free Ca(2+) concentrations by cholinergic receptors in rat facial nucleus, and the mechanisms of the modulations. METHODS: The fluorescence intensity of facial nucleus in Fluo-3 AM loaded acute brainstem slices was detected by applying intracellular free Ca(2+) measurement technique via confocal laser scanning microscope. The changes of fluorescence intensity of facial nucleus indicate the average changes of intracellular free Ca(2+) levels of the neurons. RESULTS: Acetylcholine was effective at increasing the fluorescence intensity of facial nucleus. Muscarine chloride induced a marked increase of fluorescence intensity in a concentration dependent fashion. The enhancement of fluorescence intensity by muscarine chloride was significantly reduced by thapsigargin (depletor of intracellular Ca(2+) store; P < 0.01), rather than Ca(2+) free artifical cerebrospinal fluid or EGTA (free Ca(2+) chelator; P > 0.05). And the increase of fluorescence intensity was also significantly inhibited by pirenzepine (M(1) subtype selective antagonist; P < 0.01) and 4-DAMP (M(3) subtype selective antagonist; P < 0.01). In addition, fluorescence intensity was markedly increased by nicotine. The enhancement of fluorescence intensity by nicotine was significantly reduced by EGTA, nifedipine (L-type voltage-gated Ca(2+) channel blocker), dihydro-beta-erythroidine (alpha4beta2 subtype selective antagonist), and in Ca(2+) free artificial cerebrospinal fluid (P < 0.01), but not in the presence of mibefradil (M-type voltage-gated Ca(2+) channel blocker) or thapsigargin (P > 0.05). CONCLUSIONS: The data provide the evidence that muscarinic receptors may induce the increase of intracellular free Ca(2+) levels through the Ca(2+) release of intracellular Ca(2+) stores, in a manner related to M(1) and M(3) subtypes of muscarinic receptors in rat facial nucleus. Nicotine may increase intracellular free Ca(2+) concentrations via the influx of extracellular Ca(2+)+ mainly across L-type voltage-gated Ca(2+) channels, in a manner related to the alpha4beta2 subtype of nicotinic receptors.
Assuntos
Cálcio/metabolismo , Nervo Facial/citologia , Neurônios Motores/efeitos dos fármacos , Neurônios Motores/metabolismo , Receptores Colinérgicos/metabolismo , Acetilcolina/farmacologia , Compostos de Anilina/administração & dosagem , Animais , Tronco Encefálico/citologia , Tronco Encefálico/efeitos dos fármacos , Tronco Encefálico/metabolismo , Diaminas/farmacologia , Feminino , Corantes Fluorescentes/administração & dosagem , Técnicas In Vitro , Masculino , Microscopia Confocal , Agonistas Muscarínicos/farmacologia , Nicotina/farmacologia , Agonistas Nicotínicos/farmacologia , Piperidinas/farmacologia , Pirenzepina/farmacologia , Ratos , Ratos Sprague-Dawley , Receptores Muscarínicos/metabolismo , Receptores Nicotínicos/metabolismo , Tropicamida/farmacologia , Xantenos/administração & dosagemRESUMO
Typical antipsychotic drugs, including haloperidol and pimozide, have been shown to produce parkinsonian motor effects such as akinesia and tremor. Furthermore, there is an antagonistic interaction between adenosine A(2A) and dopamine D(2) receptors in the basal ganglia, which is important for motor functions related to the production of parkinsonian symptoms. Several experiments were conducted to assess the effects of the selective adenosine A(2A) antagonist KW 6002 on both the motor and cellular effects of subchronic administration of pimozide. The motor test employed was tremulous jaw movements, which is used as a model of parkinsonian tremor. In addition, c-Fos expression in the ventrolateral neostriatum, which is the striatal area most associated with tremulous jaw movements, was used as a marker of striatal cell activity in animals that were tested in the behavioral experiments. Repeated administration of 1.0 mg/kg pimozide induced tremulous jaw movements and increased ventrolateral striatal c-Fos expression, while administration of 20.0 mg/kg of the atypical antipsychotic quetiapine did not. The tremulous jaw movements induced by pimozide were significantly reduced by co-administration of either the adenosine A(2A) antagonist KW 6002 or the muscarinic antagonist tropicamide. Pimozide-induced increases in ventrolateral striatal c-Fos expression were reduced by a behaviorally effective dose of KW 6002, but c-Fos expression in pimozide-treated rats was actually increased by tropicamide. These results indicate that two different drug manipulations that act to reduce tremulous jaw movements can have different effects on DA antagonist-induced c-Fos expression, suggesting that adenosine A(2A) antagonism and muscarinic receptor antagonism exert their motor effects by acting on different striatal circuits.
Assuntos
Antagonistas do Receptor A2 de Adenosina , Corpo Estriado/efeitos dos fármacos , Pimozida/antagonistas & inibidores , Purinas/farmacologia , Tremor/tratamento farmacológico , Tropicamida/farmacologia , Animais , Antipsicóticos/efeitos adversos , Antipsicóticos/antagonistas & inibidores , Biomarcadores/análise , Biomarcadores/metabolismo , Corpo Estriado/metabolismo , Corpo Estriado/fisiopatologia , Modelos Animais de Doenças , Antagonistas dos Receptores de Dopamina D2 , Relação Dose-Resposta a Droga , Interações Medicamentosas , Masculino , Músculos da Mastigação/inervação , Músculos da Mastigação/fisiopatologia , Antagonistas Muscarínicos/farmacologia , Pimozida/efeitos adversos , Proteínas Proto-Oncogênicas c-fos/efeitos dos fármacos , Proteínas Proto-Oncogênicas c-fos/metabolismo , Ratos , Ratos Sprague-Dawley , Receptor A2A de Adenosina/metabolismo , Receptores de Dopamina D2/metabolismo , Tremor/induzido quimicamente , Tremor/fisiopatologia , Regulação para Cima/efeitos dos fármacos , Regulação para Cima/fisiologiaRESUMO
1 In the present study we have investigated the expression of muscarinic receptors in K562 erythroleukaemic cells and the effects of muscarinic agonist and antagonists on extracellular citrulline levels in these cells, as a marker of nitric oxide (NO) generation. 2 Muscarinic acetylcholine receptors (M(1)-M(5)) play key roles in regulating many diverse physiological processes. Recent studies suggest that muscarinic receptors mediate some cellular events in haematopoietic cells. Multiple subtypes of muscarinic receptors are expressed in different human cells. NO, a free radical and a signaling molecule, is involved in the regulation of many physiological functions and derived from certain nitric oxide synthases (NOS), which are related to muscarinic receptors. 3 In this study, the presence of M(2), M(3) and M(4) subtypes in K562, an erythroleukaemic cell line, was demonstrated by using the reverse transcriptase-polymerase chain reaction. Moreover, the generation of NO induced by carbachol, a non-selective muscarinic agonist, was investigated by using high-performance liquid chromatography to measure changes in extracellular l-citrulline levels. 4 We found that carbachol enhanced l-citrulline production in K562 erythroleukaemic cells. The effect of carbachol on l-citrulline production was antagonized by atropine and 4-diphenylacetoxy-N-methylpiperidine (4-DAMP), while tropicamide had little effect. These results suggest that the muscarinic receptor M(3) subtype may mediate NO signaling in K562 erythroleukaemic cells.
Assuntos
Óxido Nítrico/metabolismo , Receptores Muscarínicos/metabolismo , Arginina/metabolismo , Carbacol/farmacologia , Cromatografia Líquida de Alta Pressão , Citrulina/metabolismo , Relação Dose-Resposta a Droga , Humanos , Células K562 , Microdiálise , Agonistas Muscarínicos/farmacologia , Antagonistas Muscarínicos/farmacologia , Óxido Nítrico/biossíntese , Óxido Nítrico Sintase/metabolismo , Piperidinas/farmacologia , RNA/biossíntese , RNA/genética , RNA/isolamento & purificação , Receptores Muscarínicos/efeitos dos fármacos , Receptores Muscarínicos/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Tropicamida/farmacologiaRESUMO
As inhibitors of acetylcholinesterase, clinical presentations of poisoning from organophosphate compounds are generally believed to entail overstimulation by the accumulated acetylcholine on muscarinic receptors at peripheral and central synapses. That some patients still yielded to acute organophosphate poisoning despite repeated dosing of atropine suggests that cellular mechanisms that are independent of muscarinic receptor activation may also be engaged in organophosphate poisoning. The present study was undertaken to test the hypothesis that muscarinic receptor-independent activation of cyclic adenosine monophosphate-dependent protein kinase A (PKA) in rostral ventrolateral medulla (RVLM), a medullary site where sympathetic vasomotor tone originates and where the organophosphate poison mevinphos (Mev) acts, is involved in the cardiovascular responses exhibited during organophosphate intoxication. In Sprague-Dawley rats, microinjection bilaterally of Mev (10 nmol) into the RVLM significantly augmented PKA activity in ventrolateral medulla that was not antagonized by coadministration of an equimolar concentration (1 nmol) of atropine or selective muscarinic receptor type M1 (pirenzepine), M2 (methoctramine), M3 (4-diphenyl-acetoxy-N-dimethylpiperidinium), or M4 (tropicamide) inhibitor. Comicroinjection of two selective PKA antagonists (100 pmol), N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide and (9R,10S,12S)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolol[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-1][1,6]benzodiazocine-10-carboxylic acid, significantly blunted the initial sympathoexcitatory cardiovascular response and the accompanying augmentation of nitric oxide synthase (NOS I) expression in the ventrolateral medulla exhibited during Mev intoxication; the secondary sympathoinhibitory phase and associated elevation in NOS II expression were unaffected. We conclude that whereas a muscarinic receptor-independent augmentation of PKA activity in the ventrolateral medulla was manifested throughout acute Mev intoxication, this activation was preferentially involved in the sympathoexcitatory phase by an upregulation of NOS I expression.